login
Current Deals

company details

ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

  • www.afdil.com/
  • Sector: Healthcare
  • CHRYSEUM SCORE: 2.50/10.00
    ×

    ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED

    • Sector: Healthcare
    • CHRYSEUM SCORE: 2.50/10.00

    Description: Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.

    Evaluation is basis the latest financial year disclosures filed by the company

    Valuation

    Max Score: 3.50

    P/E of Company

    -10.99

    AVG P/E of Key Peer/s

    33.02

    Valuation Score

    0.00

    The Valuation Score depicts if the company is available at a discount when compared to its listed/unlisted peers. Higher the discount, more is the score given to the company.

    Growth

    Max Score: 3.50

    Sales Growth

    -14.77%

    PAT Growth

    0.00%

    ROE

    -7.22%

    Growth Score

    1.00

    The Growth Score accounts for the growth in Sales and PAT on a 3 year CAGR basis and the Company’s ROE as per the latest financial year results released by the company.

    Leverage

    Max Score: 1.50

    Debt / Equity

    0.05

    AVG Industry Debt / Equity

    0.01

    Leverage Score

    0.00

    Lower the Debt/Equity, higher the score.

    Management Quality

    Max Score: 1.50

    Board Structure & Composition

    1.00

    Related Party Transactions

    1.00

    Timely Disclosure

    1.00

    Management Score

    1.50

    This score represents a consolidated view of the Company’s Management Quality, which includes Board Structure, Related Party Transactions and Timely disclosures. Each parameter is scored out of 1.

₹1100.00 0.00 (0.00%)

As on 18 Apr, 2025
L 1100.00 52 Week Range H 1100.00
Company Description : Anglo-French Drugs and Industries has market leading brands in nutraceuticals, CNS, skin and respiratory segments.
Company Overview
  • Name of Company ANGLO-FRENCH DRUGS & INDUSTRIES LIMITED
  • Sector Healthcare
  • ISIN INE570E01016
  • Scrip Code ANGLO FRENCH
  • CIN L24230KA1923PLC010205
  • Pan No AAACA9756E
  • Face Value 10
  • Price ₹ 1100.00
  • No. of Shares outstanding 0.12 Cr.
  • Market Cap ₹ 135.67 Cr
Financials
  • Revenue from operations ₹ 95.20 Cr.
  • EBITDA ₹ -7.29 Cr.
  • EBITDA Margin % -7.66%
  • Profit After Tax ₹ -12.34 Cr.
  • PAT Margin % -12.36%
  • EPS -100.05
  • Stock P/E -10.99
  • Book Value Per Share 1,385.62
  • P/B 0.79
  • Debt/Equity 0.05
Other Key Statistics
  • 52 week High/Low 1100.00/1100.00
  • Dividend Per Share 1.50
  • Dividend Yield 0.14%
  • Sales Growth - 3 years -14.77%
  • EBITDA Growth - 3 years NA
  • PAT Growth - 3 years NA
  • EPS Growth - 3 years NA
  • ROE -7.22%
  • ROCE -5.68%
  • Cash Equivalents 2.49
All figures below are in INR Crores unless otherwise stated

Peer Comparison

Key Financials - FY24
Company Name Anglo-French Drugs and Industries Ltd Marksans Pharma Ltd
Listing Status Unlisted Listed
Revenue from Operations 95.20 2,177.41
Total Income 99.84 2,227.83
Finance Cost 1.85 11.20
Depreciation & Amortization 3.15 74.27
Total Expenses 112.13 1,804.30
EBITDA -7.29 509.00
PAT -12.34 314.90
No. of Shares Outstanding 0.12 45.32
EPS (in ₹) -100.05 5.88
Share Capital 1.23 45.32
Total Net Worth 170.90 2,085.91
Total Assets 219.60 2,680.95
Total Debt 8.82 29.09
Key Metrics:
CMP* 1,100.00 211.44
Market Cap (In Cr.) 135.67 9,582.46
Market Cap/Sales 1.36 4.30
EPS (Earnings Per Share) -100.05 5.88
BVPS (Book Value Per Share) 1,385.62 46.03
P/E -10.99 35.96
P/BV 0.79 4.59
EBITDA Margin -7.66% 23.38%
ROE -7.22% 15.10%
ROA -5.62% 11.75%
*Market Price in ₹ as on 18 Apr, 2025

Profit Loss

FY24 FY23 FY22 FY21 FY20
Revenue from operations 95.20 102.51 164.80 153.78 130.18
Y-o-Y Revenue Growth -7.13% -37.80% 7.17% 18.13% 0.81%
Other Income 4.64 7.59 0.81 1.02 1.55
Total Income 99.84 110.10 165.61 154.80 131.73
Total Expenses (Excludes Interest and Depreciation) 107.13 143.88 156.63 137.42 117.80
Operating Profit (After deducting Depreciation) -15.08 -44.71 5.27 13.90 9.84
OPM % -15.84 -43.62 3.20 9.04 7.56
EBITDA -7.29 -33.78 8.98 17.38 13.93
Depreciation 3.15 3.34 2.90 2.46 2.54
EBIT -10.44 -37.12 6.08 14.92 11.39
Interest 1.85 3.07 4.27 5.29 6.17
EBT before Exceptional Items -12.29 -40.19 1.81 9.63 5.22
Prior period/Exceptional /Extra Ordinary Items 0.00 291.27 0.00 0.00 1.56
Profit before tax/EBT -12.29 251.08 1.81 9.63 3.66
Tax 0.05 60.14 0.36 2.12 0.55
Net Profit -12.34 190.94 1.45 7.51 3.11
Profit (loss) of minority interest 0.00 0.00 0.00 0.00 0.00
Total profit (loss) for period -12.34 190.94 1.45 7.51 3.11
EPS in Rs -100.05 1,478.44 11.23 58.22 26.72
EPS Change % -106.77% 13,065.09% -80.71% 117.89% -465.53%
EBITDA Change % -78.42% -476.17% -48.33% 24.77% 82.33%
Profit growth -106.46% 13,068.28% -80.69% 141.48% -465.88%
ROCE -5.68% -15.81% 12.60% 40.23% 56.84%
ROE -7.22% 91.43% 7.86% 46.73% 47.77%
Debt / Equity Ratio 0.05 0.12 1.88 2.47 6.14
Sales growth 3Years -14.77%
Sales growth 5Years -5.92%
Dividend per share 1.50 20.00 1.50

Balance Sheet

FY24 FY23 FY22 FY21 FY20
Share Capital 1.23 1.29 1.29 1.29 1.16
Reserves 169.67 207.55 17.15 14.78 5.35
Total shareholders' funds 170.90 208.84 18.44 16.07 6.51
Borrowings 8.82 26.06 34.68 39.71 40.00
Other Liabilities 15.10 16.82 19.68 16.05 17.92
Total Liabilities 48.70 64.01 77.20 78.70 86.57
Fixed Assets 17.57 17.94 18.73 13.58 15.27
Capital WIP 0.00 0.00 0.00 0.00 0.00
Investments 125.20 166.99 0.20 0.08 0.05
Other Assets 20.40 10.41 8.28 6.93 8.48
Total Assets 219.60 272.85 95.65 94.77 93.08
Cash Equivalents 2.49 9.14 1.85 1.22 0.64
Total Current liability 35.67 38.07 47.40 57.68 73.04
Total Assets -Total Current liabilty 183.93 234.78 48.25 37.09 20.04

Cash Flow

FY24 FY23 FY22 FY21 FY20
Net Cash from / (used in) Operating Activity -0.04 184.69 11.71 4.51 15.14
Net Cash from / (used in) Investing Activity 41.36 -170.40 -9.05 -0.79 -2.74
Net Cash from / (used in) Financing Activity -44.06 -11.70 -2.87 -3.31 -12.39
Net Inc/Dec In Cash And Cash Equivalents -2.74 2.59 -0.21 0.41 0.01

Share Holding Pattern

No. of Shares in Crs. % Holding
Promoters 0.08 65.24%
Non Promoters 0.04 34.76%

News

© 2022 Chryseum Advisors LLP. All rights reserved. LLPIN – AAD-0626

+91 98925 31672 | info@chryseum.in

For latest updates

Linkedin-in